Novel strategy for a bispecific antibody: induction of dual target internalization and degradation

Patient-derived cell models as preclinical tools for genome-directed targeted therapy

(2015) Ji Yun Lee et al.   Oncotarget

HER2-positive gastric cancer with concomitant MET and/or EGFR overexpression: A distinct subset of patients for dual inhibition therapy

(2014) Sang Yun Ha et al.   INTERNATIONAL JOURNAL OF CANCER

Synthetic lethal screening reveals FGFR as one of the combinatorial targets to overcome resistance to Met-targeted therapy

(2014) B Kim et al.   ONCOGENE

High-Throughput Sequencing and Copy Number Variation Detection Using Formalin Fixed Embedded Tissue in Metastatic Gastric Cancer

(2014) Seokhwi Kim et al.   PLoS One

USP8 modulates ubiquitination of LRIG1 for Met degradation

(2014) Young Mi Oh et al.   Scientific Reports

Increased TGF-  as a Mechanism of Acquired Resistance to the Anti-EGFR Inhibitor Cetuximab through EGFR-MET Interaction and Activation of MET Signaling in Colon Cancer Cells

(2013) T. Troiani et al.   CLINICAL CANCER RESEARCH

Epidermal Growth Factor Receptor: Pathway, Therapies, and Pipeline

(2013) John R. Goffin et al.   CLINICAL THERAPEUTICS

Molecular Mechanism of 17-Allylamino-17-demethoxygeldanamycin (17-AAG)-induced AXL Receptor Tyrosine Kinase Degradation

(2013) Gnana Prakasam Krishnamoorthy et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer

(2013) David R. Spigel et al.   JOURNAL OF CLINICAL ONCOLOGY

A novel bispecific EGFR/Met antibody blocks tumor-promoting phenotypic effects induced by resistance to EGFR inhibition and has potent antitumor activity

(2013) R Castoldi et al.   ONCOGENE

Antibody Therapeutics in Cancer

(2013) M. X. Sliwkowski et al.   SCIENCE

The c-Met Inhibitors: A New Class of Drugs in the Battle Against Advanced Nonsmall- Cell Lung Cancer

(2012) Assunta Sgambato et al.   CURRENT PHARMACEUTICAL DESIGN

The Therapeutic Target Hsp90 and Cancer Hallmarks

(2012) Yoshihiko Miyata et al.   CURRENT PHARMACEUTICAL DESIGN

A novel disulfide-stabilized single-chain variable antibody fragment against rabies virus G protein with enhanced in vivo neutralizing potency

(2012) Ye Duan et al.   MOLECULAR IMMUNOLOGY

A new anti-c-met antibody selected by a mechanism-based dual-screening method: Therapeutic potential in cancer

(2012) Young Mi Oh et al.   MOLECULES AND CELLS

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion

(2012) Ravid Straussman et al.   NATURE

Cbl-independent degradation of Met: ways to avoid agonism of bivalent Met-targeting antibody

(2012) J M Lee et al.   ONCOGENE

HGF induces novel EGFR functions involved in resistance formation to tyrosine kinase inhibitors

(2012) S Gusenbauer et al.   ONCOGENE

Non-Agonistic Bivalent Antibodies That Promote c-MET Degradation and Inhibit Tumor Growth and Others Specific for Tumor Related c-MET

(2012) Sameer A. Greenall et al.   PLoS One

Towards a universal disulphide stabilised single chain Fv format: importance of interchain disulphide bond location and vL-vH orientation

(2012) E. E. Weatherill et al.   PROTEIN ENGINEERING DESIGN & SELECTION

Current prospects for RNA interference-based therapies

(2011) Beverly L. Davidson et al.   NATURE REVIEWS GENETICS

HGF-independent potentiation of EGFR action by c-Met

(2011) A M Dulak et al.   ONCOGENE

c-MET as a potential therapeutic target and biomarker in cancer

(2011) J. Rafael Sierra et al.   Therapeutic Advances in Medical Oncology

Acquired Resistance of Non-Small Cell Lung Cancer Cells to MET Kinase Inhibition Is Mediated by a Switch to Epidermal Growth Factor Receptor Dependency

(2010) U. McDermott et al.   CANCER RESEARCH

HGF Rescues Colorectal Cancer Cells from EGFR Inhibition via MET Activation

(2010) D. Liska et al.   CLINICAL CANCER RESEARCH

New strategies to overcome limitations of reversible EGFR tyrosine kinase inhibitor therapy in non-small cell lung cancer

(2010) Robert C. Doebele et al.   LUNG CANCER

Targeting HSP90 for cancer therapy

(2009) D Mahalingam et al.   BRITISH JOURNAL OF CANCER

Targeting MET as a strategy to overcome crosstalk-related resistance to EGFR inhibitors

(2009) Michalis V Karamouzis et al.   LANCET ONCOLOGY

Hsp90 Is an Essential Regulator of EphA2 Receptor Stability and Signaling: Implications for Cancer Cell Migration and Metastasis

(2009) B. Annamalai et al.   MOLECULAR CANCER RESEARCH

Construction of a large synthetic human scFv library with six diversified CDRs and high functional diversity

(2009) Hye Young Yang et al.   MOLECULES AND CELLS

MetMAb, the One-Armed 5D5 Anti-c-Met Antibody, Inhibits Orthotopic Pancreatic Tumor Growth and Improves Survival

(2008) H. Jin et al.   CANCER RESEARCH

Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members

(2008) D L Wheeler et al.   ONCOGENE